
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is primed for long-term success with their expanding portfolio in the transplant rejection and oncology testing spaces, and recent financial growth and acquisitions suggest a positive outlook. However, potential risks include slow adoption of new products as CareDx enters the oncology market with their new test, AlloHeme. Their current revenue, expected to increase with recent acquisitions and divestitures, also indicates potential for long-term financial growth by 2027.
Bears say
CareDx is a healthcare company focused on precision medicine for transplant patients, known for its AlloMap and AlloSure tests. With a majority of its revenue coming from testing services, the company is expanding into new markets such as oncology with recent acquisitions. Upcoming earnings call and positive revisions to future revenue guidance, along with new acquisition and partnership opportunities, make it a promising stock in the long term. However, concerns about the impact of inorganic growth and potential dilution of shares could result in volatility and a potential decrease in stock value in the short term.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares